ES2472190R1 - Suspensión oleosa de metronidazol - Google Patents

Suspensión oleosa de metronidazol Download PDF

Info

Publication number
ES2472190R1
ES2472190R1 ES201331870A ES201331870A ES2472190R1 ES 2472190 R1 ES2472190 R1 ES 2472190R1 ES 201331870 A ES201331870 A ES 201331870A ES 201331870 A ES201331870 A ES 201331870A ES 2472190 R1 ES2472190 R1 ES 2472190R1
Authority
ES
Spain
Prior art keywords
oily suspension
metronidazole
metronidazol
giardiosis
diarrhea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201331870A
Other languages
English (en)
Other versions
ES2472190B1 (es
ES2472190A2 (es
Inventor
Fanny MARTINS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virbac SA
Original Assignee
Virbac SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virbac SA filed Critical Virbac SA
Publication of ES2472190A2 publication Critical patent/ES2472190A2/es
Publication of ES2472190R1 publication Critical patent/ES2472190R1/es
Application granted granted Critical
Publication of ES2472190B1 publication Critical patent/ES2472190B1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Suspensión oleosa de metronidazol.#La presente invención se refiere a una composición farmacéutica veterinaria oral apetente consistente en una suspensión oleosa de metronidazol y que comprende metronidazol en un aceite comestible animal, vegetal o mineral, y a su utilización para el tratamiento de la diarrea en animales, particularmente de la giardiosis, o incluso de enfermedades inflamatorias del aparato digestivo.
ES201331870A 2012-12-27 2013-12-19 Suspensión oleosa de metronidazol Active ES2472190B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1262823 2012-12-27
FR1262823A FR3000400B1 (fr) 2012-12-27 2012-12-27 Suspension huileuse de metronidazole

Publications (3)

Publication Number Publication Date
ES2472190A2 ES2472190A2 (es) 2014-06-30
ES2472190R1 true ES2472190R1 (es) 2014-08-13
ES2472190B1 ES2472190B1 (es) 2015-08-17

Family

ID=48224911

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201331870A Active ES2472190B1 (es) 2012-12-27 2013-12-19 Suspensión oleosa de metronidazol

Country Status (6)

Country Link
US (2) US20150335620A1 (es)
DE (1) DE202013011160U1 (es)
ES (1) ES2472190B1 (es)
FR (1) FR3000400B1 (es)
NZ (1) NZ631451A (es)
WO (1) WO2014102678A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112543635A (zh) * 2018-05-29 2021-03-23 Irp健康股份有限公司 硝基咪唑制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2335204A1 (fr) * 1975-12-20 1977-07-15 Bayer Ag Nouvelles formulations de niclosamide en suspension
WO2003099259A1 (fr) * 2002-05-14 2003-12-04 Virbac S.A. Compositions orales huileuses antiparasitaires

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB939681A (es)
US3178446A (en) 1961-07-27 1965-04-13 Luso Farmaco Inst Oxyethylation of imidazole compounds
FR1379915A (fr) 1963-12-17 1964-11-27 Rhone Poulenc Sa Procédé de préparation de dérivés de l'imidazole
IE59934B1 (en) * 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
CA2466083A1 (en) * 2001-11-06 2003-05-15 Maxim Pharmaceuticals, Inc. Compositions for the treatment of infectious diseases
FR2848855B1 (fr) 2002-12-23 2005-02-11 Aventis Pharma Sa Compositions pour administration orale de principes actifs necessitant un masquage du gout
BR0318319A (pt) * 2003-05-25 2006-07-18 Yuwan Wang métodos de preparação e formulações/composições sustentadas pelo uso de dimeticona como veìculo
US9055765B2 (en) * 2008-01-25 2015-06-16 Northwestern University Dietary compositions and related methods of use
WO2009143524A2 (en) * 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2335204A1 (fr) * 1975-12-20 1977-07-15 Bayer Ag Nouvelles formulations de niclosamide en suspension
WO2003099259A1 (fr) * 2002-05-14 2003-12-04 Virbac S.A. Compositions orales huileuses antiparasitaires

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Mims/mydr: ¿Flagyl ¿ Consumer Medicine Information¿, 01.09.2009, páginas 1-2, XP055071616, Recuperado de internet: URL:http://www.mydr.com.au/cmis/ReducedPDFs/CMR07087.pdf [recuperado el 16.07.2013]. *
Rosemont Pharmaceutical Ltd: ¿Norzol 200mg/5ml Oral Suspension¿, Patient Information Leaflet, 01-03-2001, páginas 1-4, XP055071604, Recuperado de internet: URL:http://www.medicines.org.uk/emc/pdfviewer.aspx?isAttachment=true&documentid=10594, [recuperado el 16.07.2013]. *
Wedgewood Pharmacy: ¿METRONIDAZOLE: ORAL OIL SUSPENSION¿, Internet Archive: Wayback Machine, 31.12.2011, páginas 1-2, XP055071326, Recuperado de internet: URL:http://web.archive.org/web/20111101164250/http://wedgewoodpetrx.com/items/metronidazole-oral-oil-suspension.html [recuperado el 15.07.2013], yWedgewood Pharmacy: ¿METRONIDAZOLE: ORAL OIL SUSPENSION¿, 31.12.2011, páginas 1-2, XP055071596, Recuperado de internet: URL:http://wedgewoodpetrx.com/items/metronidazole-oral-oil-suspension.html [recuperado el 15.07.2013]. *

Also Published As

Publication number Publication date
FR3000400A1 (fr) 2014-07-04
WO2014102678A1 (fr) 2014-07-03
ES2472190B1 (es) 2015-08-17
NZ631451A (en) 2017-02-24
US10426840B2 (en) 2019-10-01
DE202013011160U1 (de) 2014-05-06
FR3000400B1 (fr) 2019-06-21
ES2472190A2 (es) 2014-06-30
US20150335620A1 (en) 2015-11-26
US20190008967A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
BR112017003948A2 (pt) composição
PH12017501146B1 (en) Chemical mitigants in animal feed and feed ingredients
CL2015002494S1 (es) Producto alimenticio para mascotas. (divisional solicitud 457-2014)
MX2017005723A (es) Alimento seco apetitoso para gatos y metodo para la preparacion del mismo.
PL2983491T3 (pl) Jadalny gryzak dla zwierząt
EP3030248A4 (en) Tall oil fatty acid for use in treatment and animal feed supplements and compositions
AR094728A1 (es) Composiciones recubiertas de producto sanitario para animales de baja densidad
CO7020929A2 (es) Utilización de tierra de blanqueo usada, obtenida del procesamiento de aceites comestibles, en la formulación de bloques alimenticios de sales y mineralse o gránulos para ganado
BR112012001997A2 (pt) Formulação revestida, aditivo para alimentação, alimentação, e, métodos de criar um animal doméstico, e de fabricar uma formulação revestida.
CL2014003119A1 (es) Método de tratamiento no terapéutico de aves de corral, cerdos o peces para reducir la relación de conversión de alimento o incrementar su ganancia de peso corporal, que comprende la adminsitración oral de beta-alanina; y alimento para aves, cerdos o peces, que comprende beta-alanina como aditivo.
MX2017001030A (es) Alimento para mascotas de larga duracion.
EP2849767A4 (en) TALLÖL SAPONIFIED FATTY ACID FOR USE IN THERAPY, FOOD SUPPLEMENTS AND ANIMAL COMPOSITIONS
GEP201706765B (en) Formulation for personal hygiene
BR112017010431A2 (pt) método para aumentar os níveis de omega-3-s em carne
CL2015001104A1 (es) Composición de la alimentación para peces
CL2017001472A1 (es) Composiciones y métodos que comprenden triglicéridos de cadena media para el tratamiento de la epilepsia.
ES2472190B1 (es) Suspensión oleosa de metronidazol
AR092187A1 (es) Composicion fortificante para bebe prematuro
AR101673A1 (es) Composición para el tratamiento de neuropatías y del dolor neuropático
CL2016003321A1 (es) Composiciones alimenticias para peces que contienen un neonicotinoide para prevenir y tratar infecciones parasitarias
BR112016029889A2 (pt) uso de biomassa tratada hidrotermicamente como ligante de micotoxinas
EP4342304A3 (en) Product and method for providing enrichment and facilitating expression of natural behaviours in pigs
BR112016029890A2 (pt) uso de biomassa tratada hidrotermicamente como ligante de patógeno
ES1114382Y (es) Remolque para repartir alimento al ganado
ES2494617B1 (es) Uso de la Garvicina A como producto antimicrobiano

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2472190

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150817